MobiHealth News September 16, 2022
The Rhythm Evaluation for AntiCoagulaTion (REACT-AF) trial will study a “pill-in-pocket” method of stroke prevention for patients with atrial fibrillation. Some participants will monitor for AFib using an Apple Watch and take blood thinners as needed.
Late last month, Northwestern University and Johns Hopkins University announced they had received about $37 million from the National Heart, Lung and Blood Institute to study a new approach to stroke prevention in patients with atrial fibrillation, an irregular heart rhythm.
The funds will support the Rhythm Evaluation for AntiCoagulaTion (REACT-AF) trial, a seven-year study that will provide some patients with an Apple Watch to monitor for AFib. They’ll be able to take blood thinners in response to a prolonged episode, while patients in...
Today's Sponsors
Today's Sponsor